Sarah M Rudman1, Kathryn P Gray2, Julie L Batista3,4, Michael J Pitt4, Edward L Giovannucci3,4,5,6, Peter G Harper1, Massimo Loda4, Lorelei A Mucci3,4, Christopher J Sweeney7,8. 1. Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK. 2. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA, USA. 3. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School Boston, Boston, MA, USA. 4. Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA. 5. Department of Nutrition, Harvard School of Public Health, Boston, MA, USA. 6. Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Boston, MA, USA. 7. Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA, USA. 8. Harvard Medical School, Boston, MA, USA.
Abstract
OBJECTIVES: To investigate the associations of host metabolic factors and metabolic syndrome on prostate cancer-specific death (PCSD) and overall survival (OS) in patients treated with androgen deprivation therapy (ADT) for biochemically recurrent disease. PATIENTS AND METHODS: The analysis included 273 patients with prostate cancer treated with ADT for rising prostate-specific antigen level after surgery or radiotherapy. Patients were assessed for the presence of diabetes, hypertension, dyslipidaemia and obesity before commencing ADT, and Adult Treatment Panel III criteria were used to assess the presence of the composite diagnosis of metabolic syndrome. A competing risks regression model was used to assess associations of time to PCSD with the metabolic conditions, while a multivariable Cox regression model was used to assess associations of OS with metabolic syndrome and metabolic conditions. RESULTS: During a median follow-up of 11.6 years, 157 patients (58%) died, of whom 58 (21%) died from prostate cancer. At the start of ADT the median (range) patient age was 74 (46-92) years and the median PSA level was 3.0 ng/mL. Metabolic syndrome was observed in 31% of patients; hypertension (68%) and dyslipidaemia (47%) were the most common metabolic conditions. No association of PCSD and metabolic syndrome status was observed. Patients with hypertension tended to have a higher cumulative incidence of PCSD than those without hypertension (sub-distribution hazard ratio [HR] 1.59, 95% confidence interval [CI] 0.89, 2.84; P = 0.11) although the difference was not statistically significant. Patients with metabolic syndrome had an increased risk of death from all causes (HR 1.56, 95% CI 1.07, 2.29; P = 0.02) when compared with patients without metabolic syndrome, as did patients with hypertension (HR 1.72, 95% CI 1.18, 2.49; P = 0.004). CONCLUSIONS: No association of PCSD and metabolic syndrome was observed in this cohort of men receiving ADT for biochemically recurrent prostate cancer. Metabolic syndrome was associated with an increased risk of death from all causes and a similar effect was also observed for patients with prostate cancer with hypertension alone.
OBJECTIVES: To investigate the associations of host metabolic factors and metabolic syndrome on prostate cancer-specific death (PCSD) and overall survival (OS) in patients treated with androgen deprivation therapy (ADT) for biochemically recurrent disease. PATIENTS AND METHODS: The analysis included 273 patients with prostate cancer treated with ADT for rising prostate-specific antigen level after surgery or radiotherapy. Patients were assessed for the presence of diabetes, hypertension, dyslipidaemia and obesity before commencing ADT, and Adult Treatment Panel III criteria were used to assess the presence of the composite diagnosis of metabolic syndrome. A competing risks regression model was used to assess associations of time to PCSD with the metabolic conditions, while a multivariable Cox regression model was used to assess associations of OS with metabolic syndrome and metabolic conditions. RESULTS: During a median follow-up of 11.6 years, 157 patients (58%) died, of whom 58 (21%) died from prostate cancer. At the start of ADT the median (range) patient age was 74 (46-92) years and the median PSA level was 3.0 ng/mL. Metabolic syndrome was observed in 31% of patients; hypertension (68%) and dyslipidaemia (47%) were the most common metabolic conditions. No association of PCSD and metabolic syndrome status was observed. Patients with hypertension tended to have a higher cumulative incidence of PCSD than those without hypertension (sub-distribution hazard ratio [HR] 1.59, 95% confidence interval [CI] 0.89, 2.84; P = 0.11) although the difference was not statistically significant. Patients with metabolic syndrome had an increased risk of death from all causes (HR 1.56, 95% CI 1.07, 2.29; P = 0.02) when compared with patients without metabolic syndrome, as did patients with hypertension (HR 1.72, 95% CI 1.18, 2.49; P = 0.004). CONCLUSIONS: No association of PCSD and metabolic syndrome was observed in this cohort of men receiving ADT for biochemically recurrent prostate cancer. Metabolic syndrome was associated with an increased risk of death from all causes and a similar effect was also observed for patients with prostate cancer with hypertension alone.
Authors: Evan Y Yu; Hongli Li; Celestia S Higano; Neeraj Agarwal; Sumanta K Pal; Ajjai Alva; Elisabeth I Heath; Elaine T Lam; Shilpa Gupta; Michael B Lilly; Yoshio Inoue; Kim N Chi; Nicholas J Vogelzang; David I Quinn; Heather H Cheng; Stephen R Plymate; Maha Hussain; Catherine M Tangen; Ian M Thompson Journal: J Clin Oncol Date: 2015-04-06 Impact factor: 44.544
Authors: Jennifer D Wu; Austin Odman; Lily M Higgins; Kathy Haugk; Robert Vessella; Dale L Ludwig; Stephen R Plymate Journal: Clin Cancer Res Date: 2005-04-15 Impact factor: 12.531
Authors: J Flanagan; P Kathryn Gray; N Hahn; J Hayes; L J Myers; C Carney-Doebbeling; C J Sweeney Journal: Ann Oncol Date: 2010-09-29 Impact factor: 32.976
Authors: Christel Häggström; Tanja Stocks; David Ulmert; Tone Bjørge; Hanno Ulmer; Göran Hallmans; Jonas Manjer; Anders Engeland; Gabriele Nagel; Martin Almqvist; Randi Selmer; Hans Concin; Steinar Tretli; Håkan Jonsson; Pär Stattin Journal: Cancer Date: 2012-10-22 Impact factor: 6.860
Authors: L R Molife; P C Fong; L Paccagnella; A H M Reid; H M Shaw; L Vidal; H-T Arkenau; V Karavasilis; T A Yap; D Olmos; J Spicer; S Postel-Vinay; D Yin; A Lipton; L Demers; K Leitzel; A Gualberto; J S de Bono Journal: Br J Cancer Date: 2010-07-13 Impact factor: 7.640
Authors: Fausto Petrelli; Alessio Cortellini; Alice Indini; Gianluca Tomasello; Michele Ghidini; Olga Nigro; Massimiliano Salati; Lorenzo Dottorini; Alessandro Iaculli; Antonio Varricchio; Valentina Rampulla; Sandro Barni; Mary Cabiddu; Antonio Bossi; Antonio Ghidini; Alberto Zaniboni Journal: JAMA Netw Open Date: 2021-03-01
Authors: Danielle Crawley; Florence Chamberlain; Hans Garmo; Sarah Rudman; Björn Zethelius; Lars Holmberg; Jan Adolfsson; Par Stattin; Paul Carroll; Mieke Van Hemelrijck Journal: Ecancermedicalscience Date: 2018-01-25